Early and late mortality after pleurodesis for malignant pleural effusion

被引:50
|
作者
Bernard, A [1 ]
de Dompsure, RB [1 ]
Hagry, O [1 ]
Favre, JP [1 ]
机构
[1] Hop Univ, Dijon, France
来源
ANNALS OF THORACIC SURGERY | 2002年 / 74卷 / 01期
关键词
D O I
10.1016/S0003-4975(02)03599-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The purpose of this study is to analyze morbidity and mortality and to determine the relative contribution of each of these potential prognosis variables for predicting morbidity and mortality in patients after pleurodesis by thoracotomy or thoracoscopy. Methods. Between March 1, 1996, and January 31, 2001, a total of 70 patients underwent pleurodesis for recurrent malignant pleural effusion. Thoracoscopy was performed in 54 patients (77%); pleurodesis was achieved by pleural abrasion (n = 15), pleurectomy (n = 5), and talc insufflation (n = 34). Thoracotomy was performed in 16 patients (23%) who also needed pleurectomy and decortication for a trapped lung. Results. Postoperative complications occurred in 24 patients (34%). Factors adversely affecting morbidity with univariate analysis included: three or four metastatic sites (p = 0.003), and thoracotomy (p = 0.009). Factors adversely affecting morbidity with multivariate analysis included: thoracotomy (p = 0.0005) and number of metastatic sites (p = 0.007). Six patient deaths (8.6%) occurred during hospitalization. Factors adversely affecting in-hospital mortality with univariate analysis included: Eastern Cooperative Oncology Group Performance Status 2 to 3 (p = 0.001), lower preoperative serum hemoglobin (p = 0.001), lower preoperative serum albumin (p = 0.0001), and thoracotomy (p = 0.03). Factors adversely affecting in-hospital mortality with multivariate analysis included: preoperative serum albumin less than 60 g/L (p = 0.007) and ECOG Performance Status 2 to 3 (p = 0.008). Twelve patients (17%) died within 90 days after surgery. Factors adversely affecting 3-month mortality with univariate analysis included: ECOG Performance Status 2 to 3 (p = 0.001), lower preoperative serum hemoglobin (p = 0.03), higher preoperative white cells (p = 0.03), lower preoperative serum albumin (p = 0.03), and preoperative thoracentesis more than once per month (p = 0.03). Factors adversely affecting 3-month mortality with multivariate analysis included: ECOG Performance Status 2 to 3 (p = 0.01), preoperative thoracentesis more than once per month (p = 0.03), three or four metastatic sites (p = 0.02), and preoperative white blood cell count greater than or equal to 12,000/mm(3) (p = 0.03). Conclusions. Thoracotomy is not indicated in patients with a malignant effusion because of poor survival, a high frequency of complications, and prolonged hospital stay. Pleurodesis thoracoscopy is indicated in patients with good performance status coupled with good nutrition. (C) 2002 by The Society of Thoracic Surgeons.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 50 条
  • [1] PLEURODESIS IN MALIGNANT PLEURAL EFFUSION
    FURRER, M
    INDERBITZI, R
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1992, 122 (06) : 181 - 188
  • [2] FIBRIN PLEURODESIS FOR MALIGNANT PLEURAL EFFUSION
    KREUSER, ED
    SEIFRIED, E
    HARSCH, U
    BRASS, B
    SCHREML, W
    HEIMPEL, H
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1985, 110 (36) : 1365 - 1368
  • [3] Chemical pleurodesis for malignant pleural effusion
    Shouman, W.
    Elgazzar, A.
    Hussien, R. M.
    ElShaaray, M.
    Light, R. W.
    [J]. EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2012, 61 (03): : 115 - 120
  • [4] Adverse events after pleurodesis in patients with malignant pleural effusion
    Terra, Ricardo Mingarini
    da Costa, Priscila Berenice
    Dela Vega, Alberto Jorge Monteiro
    Pego-Fernandes, Paulo Manuel
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (07) : 3507 - 3513
  • [5] Interstitial Lung Disease after Pleurodesis for Malignant Pleural Effusion
    Yokoe, Norihito
    Katsuda, Eisuke
    Kosaka, Kenshi
    Hamanaka, Rie
    Matsubara, Ayako
    Nishimura, Masaki
    Tanaka, Hiroyuki
    Asai, Nobuhiro
    Takahashi, Ayumu
    Kawamura, Toshiki
    Ishiguchi, Tsuneo
    Yamaguchi, Etsuro
    Kubo, Akihito
    [J]. INTERNAL MEDICINE, 2017, 56 (14) : 1791 - 1797
  • [6] Thoracic Ultrasound as an Early Predictor of Pleurodesis Success in Malignant Pleural Effusion
    Corcoran, John P.
    Hallifax, Robert J.
    Mercer, Rachel M.
    Yousuf, Ahmed
    Asciak, Rachelle
    Hassan, Maged
    Piotrowska, Hania E.
    Psallidas, Ioannis
    Rahman, Najib M.
    [J]. CHEST, 2018, 154 (05) : 1115 - 1120
  • [7] Early Thoracic Ultrasound to Assess Success of Pleurodesis in malignant Pleural Effusion
    Acton, Vincent
    [J]. CHEST, 2019, 155 (03) : 648 - 649
  • [8] OUTCOMES OF TALC PLEURODESIS IN MALIGNANT PLEURAL EFFUSION
    Guerra, S.
    Ferro, R.
    Conceicao, M.
    Cunha, A.
    Antonio, C.
    Simoes Torres, A.
    [J]. CHEST, 2020, 157 (06) : 350A - 350A
  • [9] Rapid pleurodesis in symptomatic malignant pleural effusion
    Yildirim, E
    Dural, K
    Yazkan, R
    Zengin, N
    Yildirim, D
    Gunal, N
    Sakinci, U
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2005, 27 (01) : 19 - 22
  • [10] Evaluation Of Talc For Pleurodesis In Malignant Pleural Effusion
    Hsieh, W.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189